You will recall final week that medical trials of the COVID-19 vaccine candidate from Oxford / AstraZeneca have been paused:
Information now that AstraZeneca mentioned it obtained notification from the UK’s Medicines Well being Regulatory Authority that it was protected to renew medical trials.
Whereas trials can now resume within the UK, elsewhere stays unclear; says AstraZeneca in a press release:
- The Firm will proceed to work with well being authorities the world over and be guided as to when different medical trials can resume to supply the vaccine broadly, equitably and at no revenue throughout this pandemic
Threat sentiment must be improved by this (partially) constructive improvement.
For financial institution commerce concepts, take a look at eFX Plus